NUVA - NuVasive, Inc.
| Previous Close | 62.05 |
| Open | 62.36 |
| Bid | 63.48 x 800 |
| Ask | 63.50 x 900 |
| Day's Range | 62.15 - 63.92 |
| 52 Week Range | 44.62 - 72.41 |
| Volume | 557,840 |
| Avg. Volume | 641,960 |
| Market Cap | 3.263B |
| Beta (3Y Monthly) | 0.66 |
| PE Ratio (TTM) | 76.45 |
| EPS (TTM) | 0.83 |
| Earnings Date | Oct 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.67 |
- MarketWatch•3 days ago
NuVasive's stock tumble on CEO departure presents buying opportunity, analyst says
Shares of NuVasive Inc. tumbled 9.1% in midday trade, after the spine technology company's announcement that it was replacing its chief executive. Since NuVasive didn't reiterated its 2018 financial guidance, Needham analyst Mike Matson suggested the big selloff is a result of investors assuming the company misses or lowers its outlook. While Matson doesn't rule out a warning, he feels the stock's selloff is now overdone. NuVasive is scheduled to report third-quarter results after the Oct. 30 closing bell. In the company second-quarter report, the company cut its 2018 adjusted earnings-per-share guidance range to $2.37 to $2.40 from $2.44 to $2.47. "While this [miss/warning] could clearly occur, with [NuVasive] shares now down significantly today we think they are sufficiently de-risked and we are buyers on the weakness," Matson wrote in a note to clients. The stock was still up 15% over the past three months, while the S&P 500 has slipped 1.2%.
- MarketWatch•3 days ago
NuVasive CEO Lucier to step down, names Chris Barry as successor
NuVasive Inc. said Chief Executive Gregory Lucier will step down effective Nov. 5, after 3 1/2-years in the role. He will continue as chairman of the board. The spine technology company said J. Christopher Barry will succeed Lucier as CEO. Barry is currently president of Medtronic PLC's Surgical Innovations business unit. The company also said Matt Link, executive vice president of strategy, technology and corporate development, is promoted to president. "The combination of Chris and Matt at the helm of NuVasive creates the most dynamic leadership team in the industry," Lucier said. The stock, which is still inactive in premarket trade, has rallied 26% over the past three months, while the S&P 500 has lost 1.3%.
- PR Newswire•3 days ago
NuVasive Names J. Christopher Barry To Succeed Gregory T. Lucier As Chief Executive Officer; Lucier To Remain Chairman Of The Board
SAN DIEGO, Oct. 19, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its Board of Directors has named J. Christopher Barry to succeed Gregory T. Lucier as chief executive officer (CEO) effective November 5, 2018. Mr. Lucier will continue to serve as chairman of the Board.
- Motley Fool•5 days ago
5 Great Stocks You've Never Heard Of: 1 Year Later, Should You Be Glad We Told You About Them?
Last September, David Gardner sifted through the less-loved end of the Supernova universe to find some neglected stocks with strong potential.
Markit•6 days agoSee what the IHS Markit Score report has to say about NuVasive Inc.
NuVasive Inc NASDAQ/NGS:NUVA
- Simply Wall St.•10 days ago
How Does NuVasive Inc’s (NASDAQ:NUVA) Earnings Growth Stack Up Against Industry Performance?
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find my Read More...
- PR Newswire•11 days ago
NuVasive Announces Conference Call And Webcast Of Third Quarter 2018 Results
SAN DIEGO, Oct. 11, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its third quarter 2018 earnings results on Tuesday, October 30, 2018 after the close of the market. NuVasive will hold a conference call on Tuesday, October 30, 2018 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter 2018. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers.
- PR Newswire•13 days ago
NuVasive Announces Strategic Partnership With Biedermann Technologies To Access Intellectual Property And Co-Develop State-of-the-Art Complex Spine Solutions
SAN DIEGO and DONAUESCHINGEN, GERMANY, Oct. 9, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it has entered into a strategic partnership with Biedermann Technologies GmbH & Co. KG, a company that holds a broad and extensive patent and technology portfolio in the fields of spinal and extremity surgery, based in Donaueschingen, Germany.
- PR Newswire•14 days ago
NuVasive Clinical Services Awarded Sole Source Intraoperative Neuromonitoring Services Contract With Premier
SAN DIEGO, Oct. 8, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive Clinical Services has been awarded a three-year, sole source supplier contract for Intraoperative Neuromonitoring (IONM) Services with Premier. Effective November 1, 2018, the new contract allows Premier members the option to take advantage of special pricing and terms pre-negotiated by Premier for IONM services provided by NuVasive Clinical Services (NCS). NCS is the largest provider of intraoperative neuromonitoring services, covering the full range of spine, brain, and other surgical procedures.
- PR Newswire•18 days ago
NuVasive To Showcase Comprehensive Solutions For Complex Spinal Deformities At Scoliosis Research Society Annual Meeting
SAN DIEGO, Oct. 4, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will highlight several of its latest spinal innovations to treat complex spinal deformities at the Scoliosis Research Society (SRS) Annual Meeting held October 10-13, 2018 in Bologna, Italy. As a Double Diamond Sponsor of SRS, NuVasive continues to demonstrate a strong leadership position in offering transformative solutions within the complex adult and pediatric deformity market segments. "The NuVasive deformity portfolio is one of the most differentiated portfolios in the market offering surgical efficiency, operative reliability and procedural versatility," said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive.
- GlobeNewswire•21 days ago
New Research Coverage Highlights Dillard's, AMC Entertainment, Patterson Companies, NuVasive, Life Storage, and Ambac Financial Group — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 01, 2018-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•24 days ago
Today's Research Reports on Trending Tickers: Accuray and NuVasive
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...
- PR Newswire•26 days ago
NuVasive Enrolls First Patients In Long-Term, Controlled Study Evaluating Advanced Implants' Effects On Fusion And Clinical Outcomes In XLIF® Procedures
SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it enrolled its first patients in a prospective, multicenter study evaluating advanced spinal implants used in XLIF® procedures and their effect on long-term patient outcomes. This study will evaluate and compare the clinical and radiographic outcomes between traditional smooth PEEK intervertebral spacers and two implants within the NuVasive Advanced Materials Science™ (AMS) portfolio, Modulus® 3D-printed titanium and Cohere® Porous PEEK™, in patients who undergo a one- or two-level XLIF procedure. In this two-year follow-up study, at least 10 surgeon investigators will measure the progression of fusion in approximately 300 patients across the U.S. Through the study's results, NuVasive seeks to drive better clinical outcomes for patients, and prove out more efficient and cost-effective procedures for surgeons and hospitals.
Markit•26 days agoSee what the IHS Markit Score report has to say about NuVasive Inc.
NuVasive Inc NASDAQ/NGS:NUVA
- PR Newswire•27 days ago
NuVasive To Demonstrate Pulse™ Surgical Automation Platform At NASS 2018 Annual Meeting
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that live demonstrations of the Pulse™ surgical automation platform with integration of the Siemens Healthineers' Cios Spin* cutting-edge mobile 3D-imaging will be held throughout the North American Spine Society (NASS) 2018 Annual Meeting, September 26-29, 2018. Upon commercial availability, the Pulse platform will incorporate NuVasive's neuromonitoring system, NuvaMap® OR surgical planning, rod bending, smart imaging, new 2D- and 3D-navigation, and automation.
- PR Newswire•28 days ago
NuVasive Expands Biologics Portfolio To Meet Clinical And Economic Needs
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the U.S. commercial launch of three new biologics offerings to include traditional bone allograft, amniotic membrane DS and additional form factors to the current PropelTM DBM product line. This portfolio expansion demonstrates the Company's strategic efforts to deliver the most differentiated biologics portfolio in the spine industry.
- PR Newswire•last month
Scott Huennekens To Join NuVasive Board Of Directors
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the appointment of Scott Huennekens to the Company's Board of Directors, effective October 1, 2018. Mr. Huennekens has over 25 years of experience in the medical device industry, with particular expertise overseeing clinical advancement through innovative R&D and technology-based initiatives.
- PR Newswire•last month
NuVasive Clinical Services™ Leader Richard Vogel Co-Chairs And Lectures At American Society Of Neurophysiological Monitoring 2018 Fall Symposium
SAN DIEGO, Sept. 11, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced Richard Vogel, Ph.D., DABNM, FASNM, director of Strategic Initiatives at NuVasive Clinical ServicesTM (NCS), will co-chair, moderate and lecture at the American Society of Neurophysiological Monitoring (ASNM) 2018 Fall Symposium held September 15-16, 2018, in Nashville, Tennessee. ASNM is the largest professional society in the world dedicated to the advancement of intraoperative neurophysiological monitoring (IONM).
- Simply Wall St.•last month
What You Must Know About NuVasive Inc’s (NASDAQ:NUVA) 5.4% ROE
I am writing today to help inform people who are new to the stock market and want to begin learning the link between company’s fundamentals and stock market performance. NuVasiveRead More...
- PR Newswire•2 months ago
NuVasive To Present At The Morgan Stanley 16th Annual Global Healthcare Conference
SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that management will present at the Morgan Stanley 16th Annual Global Healthcare Conference at the Grand Hyatt New York in New York City on Wednesday, September 12, 2018, at 2:15 p.m. ET/11:15 a.m. PT. NuVasive, Inc. (NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes.
- PR Newswire•2 months ago
NuVasive Grows Expandable Spinal Interbody Portfolio With Launch Of TLX® 20 Degree Implant
SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the launch of its TLX® 20 degree expandable spinal interbody implant with a first-of-its-kind oblique profile designed for transforaminal lumbar interbody fusion (TLIF) procedures. This product launch is another step forward in the Company's strategy to build a comprehensive expandable portfolio to best support optimal clinical outcomes. The implant profile is designed to optimally contour to a patient's interdiscal space to help maintain coronal alignment while achieving sagittal correction, an important aspect of desired patient outcomes that has been clinically validated through research and data from NuVasive's Integrated Global Alignment® (iGA®) platform.
- PR Newswire•2 months ago
NuVasive To Feature Lateral Single-Position Surgery And Surgical Intelligence At SMISS Annual Forum
During SMISS 2018, NuVasive will feature its Lateral Single-Position Surgery procedure benefits, which may include reducing the number of times a patient has to be repositioned for greater operating room (OR) efficiency, along with the other benefits of minimally invasive spine surgery. Attendees will hear directly from leading surgeons of the procedure and learn what NuVasive is doing to incorporate advanced materials into its surgical implants.
- Zacks•2 months ago
Why Is NuVasive (NUVA) Up 8.3% Since Last Earnings Report?
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Markit•2 months agoSee what the IHS Markit Score report has to say about NuVasive Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
